Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI ...

Funding led by Lightspeed with participation from WndrCo, Amplify Partners and others, Reactor provides the infrastructure layer for real-time generative video SAN FRANCISCO, May 28, 2026 — Reactor, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A former employee of Tempus AI, Inc. has sued the Illinois-based company in federal court, alleging that her complaints to human resources about a hostile work environment triggered a months-long ...

Tempus AI is a diagnostics and data platform leveraging a large healthcare dataset to inform clinical decision-making. Strong 2025 performance driven by diagnostics growth, oncology re-acceleration, ...

The legal pressure on Tempus—which uses its massive trove of genetic information to train AI algorithms used in patient care—comes amid growing national concern over the commoditization of DNA data. A ...

Tempus AI is rated Strong Buy with a $71 12-month price target, reflecting 67% upside after a 60% share price decline. TEM's integrated genomic and clinical data flywheel creates a defensible moat, ...

Tempus AI (NASDAQ:TEM) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis. Tempus reported preliminary Q4 revenue of $367M, up 83% ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 ...